Curis wins patent for treatment of chronic kidney disease

[Guest guest]

http://www.masshightech.com/displayarticledetail.asp?art_ID=67990

This group evidently spun out of some of the research work done at Brigham

and Women's in Boston. If I remember correctly, they claimed that

injections of this BMP-7 protein into the kidney had the potential to cause

the glomuleri to repair and/or grow again. Obviously, this patent is a long

way from a usable drug, but it somewhat indicates that they are on their way

to starting some kind of trials -- they state they are in " Late Preclinical

Trials " . They also state that they believe the market is as large as Epogen

-- and would serve the same market. You can read more about their current

status at http://www.curis.com/product_kidney.html

Curis wins patent for treatment of chronic kidney disease

03/02/2005 10:44 AM

Curis Inc. has announced that it has been issued a U.S. patent for

technology to treat chronic renal failure.

Cambridge-based Curis is a public drug development company. Company

officials say there are 423,000 patients in the United States with end-stage

renal disease.

The claims of this patent outline methods for improving kidney function by

activation of the bone morphogenetic protein (BMP) pathway through the

administration of BMP-7 or a related protein.

The company's technology focus is on regulatory pathways that control repair

and regeneration. Curis' product development involves the use of proteins or

small molecules to modulate these pathways.

Its stock price opened today at $3.78, down 12 cents from yesterday's close

_____

[Guest guest]

Hmm, I used to own stock in this company a few years ago when biotech

was really hot. Maybe I'll have to buy them again! Only around $4 a

share at the moment.

If anyone's interested, there's more detailed information about

research regarding BMP-7 and chronic kidney disease on their website at:

http://www.curis.com/product_kidney.html

-Jack

>

> http://www.masshightech.com/displayarticledetail.asp?art_ID=67990

>

> This group evidently spun out of some of the research work done at

Brigham

> and Women's in Boston. If I remember correctly, they claimed that

> injections of this BMP-7 protein into the kidney had the potential

to cause

> the glomuleri to repair and/or grow again. Obviously, this patent

is a long

> way from a usable drug, but it somewhat indicates that they are on

their way

> to starting some kind of trials -- they state they are in " Late

Preclinical

> Trials " . They also state that they believe the market is as large

as Epogen

> -- and would serve the same market. You can read more about their

current

> status at http://www.curis.com/product_kidney.html

>

>

>

>

>

> Curis wins patent for treatment of chronic kidney disease

>

> 03/02/2005 10:44 AM

>

> Curis Inc. has announced that it has been issued a U.S. patent for

> technology to treat chronic renal failure.

>

> Cambridge-based Curis is a public drug development company. Company

> officials say there are 423,000 patients in the United States with

end-stage

> renal disease.

>

> The claims of this patent outline methods for improving kidney

function by

> activation of the bone morphogenetic protein (BMP) pathway through the

> administration of BMP-7 or a related protein.

>

> The company's technology focus is on regulatory pathways that

control repair

> and regeneration. Curis' product development involves the use of

proteins or

> small molecules to modulate these pathways.

>

> Its stock price opened today at $3.78, down 12 cents from

yesterday's close

>

>

> _____

>

>

>

>

>

[Guest guest]

Hmm, I used to own stock in this company a few years ago when biotech

was really hot. Maybe I'll have to buy them again! Only around $4 a

share at the moment.

If anyone's interested, there's more detailed information about

research regarding BMP-7 and chronic kidney disease on their website at:

http://www.curis.com/product_kidney.html

-Jack

>

> http://www.masshightech.com/displayarticledetail.asp?art_ID=67990

>

> This group evidently spun out of some of the research work done at

Brigham

> and Women's in Boston. If I remember correctly, they claimed that

> injections of this BMP-7 protein into the kidney had the potential

to cause

> the glomuleri to repair and/or grow again. Obviously, this patent

is a long

> way from a usable drug, but it somewhat indicates that they are on

their way

> to starting some kind of trials -- they state they are in " Late

Preclinical

> Trials " . They also state that they believe the market is as large

as Epogen

> -- and would serve the same market. You can read more about their

current

> status at http://www.curis.com/product_kidney.html

>

>

>

>

>

> Curis wins patent for treatment of chronic kidney disease

>

> 03/02/2005 10:44 AM

>

> Curis Inc. has announced that it has been issued a U.S. patent for

> technology to treat chronic renal failure.

>

> Cambridge-based Curis is a public drug development company. Company

> officials say there are 423,000 patients in the United States with

end-stage

> renal disease.

>

> The claims of this patent outline methods for improving kidney

function by

> activation of the bone morphogenetic protein (BMP) pathway through the

> administration of BMP-7 or a related protein.

>

> The company's technology focus is on regulatory pathways that

control repair

> and regeneration. Curis' product development involves the use of

proteins or

> small molecules to modulate these pathways.

>

> Its stock price opened today at $3.78, down 12 cents from

yesterday's close

>

>

> _____

>

>

>

>

>

[Guest guest]

Hmm, I used to own stock in this company a few years ago when biotech

was really hot. Maybe I'll have to buy them again! Only around $4 a

share at the moment.

If anyone's interested, there's more detailed information about

research regarding BMP-7 and chronic kidney disease on their website at:

http://www.curis.com/product_kidney.html

-Jack

>

> http://www.masshightech.com/displayarticledetail.asp?art_ID=67990

>

> This group evidently spun out of some of the research work done at

Brigham

> and Women's in Boston. If I remember correctly, they claimed that

> injections of this BMP-7 protein into the kidney had the potential

to cause

> the glomuleri to repair and/or grow again. Obviously, this patent

is a long

> way from a usable drug, but it somewhat indicates that they are on

their way

> to starting some kind of trials -- they state they are in " Late

Preclinical

> Trials " . They also state that they believe the market is as large

as Epogen

> -- and would serve the same market. You can read more about their

current

> status at http://www.curis.com/product_kidney.html

>

>

>

>

>

> Curis wins patent for treatment of chronic kidney disease

>

> 03/02/2005 10:44 AM

>

> Curis Inc. has announced that it has been issued a U.S. patent for

> technology to treat chronic renal failure.

>

> Cambridge-based Curis is a public drug development company. Company

> officials say there are 423,000 patients in the United States with

end-stage

> renal disease.

>

> The claims of this patent outline methods for improving kidney

function by

> activation of the bone morphogenetic protein (BMP) pathway through the

> administration of BMP-7 or a related protein.

>

> The company's technology focus is on regulatory pathways that

control repair

> and regeneration. Curis' product development involves the use of

proteins or

> small molecules to modulate these pathways.

>

> Its stock price opened today at $3.78, down 12 cents from

yesterday's close

>

>

> _____

>

>

>

>

>

[Guest guest]

Any research is exciting when it comes to kidney disease and renal failure.

The more the better.

I'm betting the first practical development to come along in the future will

be a kind of dialyzer (the articifical kidney that goes on the dialysis

machine) with a membrane lined with the person's own kidney cells.

Pierre

[Guest guest]

My husband and I are interested in buying stock on this. Could you tell me

what exchange it is on and how it's listed?

Thanks!

Angel...Cades mom

[Guest guest]

This stock is on the NASDAQ National market under the symbol CRIS. Keep in

mind that this is a stock that is losing money, has only one product that

they have talked about, and the product is not yet through any kind of

clinical trials. It is just as likely that the company goes completely

under and never does anything as that it sells out to some big pharma

company and you make a whopping $1.00/share. If you are not afraid to lose

all of the money that you put into it, then you can buy this through any

brokerage account that you currently have -- right now it is relatively

inexpensive, but could become even more so if any one of the trials fails...

Walt

_____

From: saturn70006@...

Sent: Saturday, March 05, 2005 9:46 PM

To: iga-nephropathy

Subject: Re: Re: Curis wins patent for treatment of chronic kidney

disease

My husband and I are interested in buying stock on this. Could you tell me

what exchange it is on and how it's listed?

Thanks!

Angel...Cades mom

[Guest guest]

Walt,

Thanks for the info

Angel

[Guest guest]

Walt's probably right. The stock never did that much for me, although

I didn't lose on it either. I first owned the stock when it was

called Creative Biomolecules and it ended up merging with another

company (forget the name) and became Curis. It never really went

anywhere although I did start playing it as a " rolling stock " and made

a few bucks off of it. It's probably going to be boom, bust, or

something you can " roll " with. It's doubtful that it'll be a buy and

hold type of investment.

-Jack

> This stock is on the NASDAQ National market under the symbol CRIS.

Keep in

> mind that this is a stock that is losing money, has only one product

that

> they have talked about, and the product is not yet through any kind

of

> clinical trials. It is just as likely that the company goes

completely

> under and never does anything as that it sells out to some big

pharma

> company and you make a whopping $1.00/share. If you are not afraid

to lose

> all of the money that you put into it, then you can buy this

through any

> brokerage account that you currently have -- right now it is

relatively

> inexpensive, but could become even more so if any one of the trials

fails...

>

> Walt

>

> _____

>

> From: saturn70006@a... [mailto:saturn70006@a...]

> Sent: Saturday, March 05, 2005 9:46 PM

> To: iga-nephropathy

> Subject: Re: Re: Curis wins patent for treatment of chronic

kidney

> disease

>

>

> My husband and I are interested in buying stock on this. Could you

tell me

> what exchange it is on and how it's listed?

>

> Thanks!

> Angel...Cades mom

>

>

>